JP2011502113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502113A5 JP2011502113A5 JP2010530588A JP2010530588A JP2011502113A5 JP 2011502113 A5 JP2011502113 A5 JP 2011502113A5 JP 2010530588 A JP2010530588 A JP 2010530588A JP 2010530588 A JP2010530588 A JP 2010530588A JP 2011502113 A5 JP2011502113 A5 JP 2011502113A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- administering
- animal
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 238000000034 method Methods 0.000 claims 17
- 241001465754 Metazoa Species 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- PNLQMIOPVBCLRV-UHFFFAOYSA-N 2-ethyldocosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CCC=CCC=CCC=CCC=CCC=CCC=CCC(CC)C(O)=O PNLQMIOPVBCLRV-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- -1 methoxy, ethoxy, propoxy, isopropoxy, sec- butoxy, phenoxy, benzyloxy Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims 2
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012039 electrophile Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US109707P | 2007-10-31 | 2007-10-31 | |
| US61/001,097 | 2007-10-31 | ||
| PCT/IB2008/003666 WO2009056983A1 (en) | 2007-10-31 | 2008-10-30 | New dha derivatives and their use as medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011502113A JP2011502113A (ja) | 2011-01-20 |
| JP2011502113A5 true JP2011502113A5 (enExample) | 2011-12-15 |
| JP5575651B2 JP5575651B2 (ja) | 2014-08-20 |
Family
ID=40374914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530588A Expired - Fee Related JP5575651B2 (ja) | 2007-10-31 | 2008-10-30 | 新規のｄｈａ誘導体およびその医薬品としての用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100267828A1 (enExample) |
| EP (1) | EP2217558A1 (enExample) |
| JP (1) | JP5575651B2 (enExample) |
| KR (1) | KR20100100818A (enExample) |
| WO (1) | WO2009056983A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2427415T3 (pl) * | 2009-05-08 | 2019-09-30 | Basf As | Wielonienasycone kwasy tłuszczowe do leczenia chorób związanych z dziedziną chorób sercowo-naczyniowych, metabolicznych i zapalnych |
| EP2248798A1 (en) * | 2009-05-08 | 2010-11-10 | Pronova BioPharma Norge AS | Novel lipid compounds |
| NZ610705A (en) | 2010-11-05 | 2014-10-31 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| JP6173352B2 (ja) | 2012-02-15 | 2017-08-02 | アニダ ファーマ インコーポレイテッド | 筋萎縮性側索硬化症の治療方法 |
| KR102213143B1 (ko) | 2013-02-28 | 2021-02-08 | 바스프 에이에스 | 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법 |
| BR112017023164A2 (en) | 2015-04-28 | 2018-07-24 | Pronova Biopharma Norge As | and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof |
| EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| BR112020011431A2 (pt) | 2017-12-06 | 2020-11-24 | Basf As | derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica |
| KR20220143931A (ko) | 2020-02-21 | 2022-10-25 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2836628A (en) * | 1955-10-17 | 1958-05-27 | Monsanto Chemicals | Unsaturated branched-chain alcohols and methods of preparing same |
| US4132719A (en) * | 1978-04-20 | 1979-01-02 | Mcneilab Inc. | Dibromoalkylglycidic acid derivatives |
| US4264517A (en) * | 1978-12-11 | 1981-04-28 | G.D. Searle & Co. | Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates |
| US4647685A (en) * | 1985-04-25 | 1987-03-03 | Eli Lilly And Company | 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US5422371A (en) * | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| JPH0692848A (ja) * | 1992-09-11 | 1994-04-05 | Sagami Chem Res Center | 糖尿病治療用乳剤 |
| JPH06192177A (ja) * | 1992-10-27 | 1994-07-12 | Sando Yakuhin Kk | グリセリン誘導体並びにこれを含有する血小板凝集抑制剤および脂肪輸液剤 |
| AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| JP4530311B2 (ja) * | 2000-07-13 | 2010-08-25 | 日本水産株式会社 | リパーゼを用いたグリセライドの製造方法 |
| JP2002180082A (ja) * | 2000-12-11 | 2002-06-26 | Maruha Corp | 摂取物 |
| US20040235948A1 (en) * | 2003-03-05 | 2004-11-25 | Solvay Pharmaceuticals Gmbh | Treatment of diabetic patients with omega-3-fatty acids |
| AU2004223980B2 (en) * | 2003-03-27 | 2010-11-11 | Suntory Holdings Limited | Lipid-improving agent and composition containing lipid-improving agent |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| US20060183174A1 (en) * | 2005-02-11 | 2006-08-17 | Leong Ng | Diagnosis |
| JP2008540394A (ja) * | 2005-05-04 | 2008-11-20 | プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ | 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用 |
| RU2509071C2 (ru) * | 2006-11-01 | 2014-03-10 | Пронова Биофарма Норге Ас | Новые липидные соединения |
| KR101438177B1 (ko) * | 2006-11-01 | 2014-09-05 | 프로노바 바이오파마 너지 에이에스 | 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질 |
-
2008
- 2008-10-30 WO PCT/IB2008/003666 patent/WO2009056983A1/en not_active Ceased
- 2008-10-30 JP JP2010530588A patent/JP5575651B2/ja not_active Expired - Fee Related
- 2008-10-30 KR KR1020107011179A patent/KR20100100818A/ko not_active Abandoned
- 2008-10-30 EP EP08844938A patent/EP2217558A1/en not_active Withdrawn
- 2008-10-30 US US12/740,377 patent/US20100267828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502113A5 (enExample) | ||
| US11685735B2 (en) | Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders | |
| CN106715456B (zh) | 定向淋巴的前药 | |
| US10258609B2 (en) | Therapeutic agent for dyslipidemia | |
| RU2009120534A (ru) | Новые липидные соединения | |
| JP7053478B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP2010508262A5 (enExample) | ||
| BR112020011431A2 (pt) | derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica | |
| JP5575651B2 (ja) | 新規のｄｈａ誘導体およびその医薬品としての用途 | |
| KR20130132836A (ko) | 지질 화합물을 이용한 치료방법 | |
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| US20230348457A1 (en) | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof | |
| CN101652134B (zh) | 用于预防和/或治疗脂肪肝或非酒精性脂肪性肝炎的药物 | |
| CN1173705C (zh) | β－2－羟甲基－5－(5－氟胞嘧啶－1－基)－1,3－噁噻戊环在制药中的应用及含有该化合物的药物组合物 | |
| JP2008530242A5 (enExample) | ||
| JP2019518738A (ja) | 組成物、ならびにその適用および薬学的調製の方法 | |
| JP2018197273A (ja) | 脂質異常症治療剤 | |
| US20250002490A1 (en) | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof | |
| JP2022523792A (ja) | 肥満及び関連する障害の予防及び治療のための化合物 | |
| KR20210015883A (ko) | 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 | |
| WO2003004484A1 (en) | Novel aliphatic compounds, synthesis method and method of using the same | |
| WO2017193563A1 (zh) | 一种组合物及其用途、药物制剂 | |
| WO2016085954A1 (en) | Geranygeranylacetone and analogs thereof and phenoxyalkylcarboxlic acids for treating fibrosis | |
| WO2010083279A2 (en) | Methods for treating disorders associated with hyperlipidemia in a mammal | |
| HK1219662B (zh) | 血脂异常症治疗剂 |